Matrix metalloproteinase inhibitors

Details for Australian Patent Application No. 2004272280 (hide)

Owner Glaxo Group Limited

Inventors Holmes, Ian Peter; Watson, Stephen Paul; Gaines, Simon; Martin, Stephen Lewis

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-B-2004272280

PCT Pub. Number WO2005/026120

Priority 0321538.1 13.09.03 GB

Filing date 10 September 2004

Wipo publication date 24 March 2005

Acceptance publication date 21 April 2011

International Classifications

C07D 239/54 (2006.01) Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings

A61K 31/4035 (2006.01)

A61K 31/505 (2006.01) - Pyrimidines

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61P 29/00 (2006.01) Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents

C07D 209/48 (2006.01) Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom

C07D 403/10 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

C07D 405/10 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

Event Publications

23 February 2006 PCT application entered the National Phase

  PCT publication WO2005/026120 Priority application(s): WO2005/026120

21 April 2011 Application Accepted

  Published as AU-B-2004272280

7 July 2011 Application for Amendment

  The nature of the amendment is as shown in the statement(s) filed 20 Jun 2011. Address for service in Australia - Phillips Ormonde Fitzpatrick 367 Collins Street Melbourne VIC 3000

27 October 2011 Amendment Made

  The nature of the amendment is as shown in the statement(s) filed 20 Jun 2011

3 November 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004272283-2,4 di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or Syk inhibitors

2004272275-1, 3-disubstituted azetidine derivatives for use as CCR-3 receptor antagonists in the treatment of inflammatory and allergic diseases